Regardless of mechanism, these studies demonstrate that anti-ACVR1 antibodies characterized to date profoundly exacerbate disease progression in FOP mice, highlighting the importance of using genetically and physiologically relevant mouse models and cell types to evaluate potential therapeutic candidates for FOP. The gene discussed is ACVR1; the disease is fibrodysplasia ossificans progressiva.